###begin article-title 0
###xml 52 53 52 53 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 61 62 61 62 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 139 145 139 140 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fn3" ref-type="fn">&#8224;</xref>
A Structure-Based Approach to Ligand Discovery for 2C-Methyl-d-erythritol-2,4-cyclodiphosphate Synthase: A Target for Antimicrobial Therapydagger
###end article-title 0
###begin p 1
###xml 134 135 134 135 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 144 146 144 146 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
The coordinates and structure factors have been deposited in the Protein Data Bank with accession codes  (FLUC),  (CVD),  (AraCMP),  (7), and  (6b).
###end p 1
###begin p 2
Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee.
###end p 2
###begin p 3
Institut fur Pharmazeutische Chemie, Philipps-Universitat, Marburg.
###end p 3
###begin p 4
###xml 180 199 180 199 <uri xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="http://pubs.acs.org">http://pubs.acs.org</uri>
This is an open-access article distributed under the ACS AuthorChoice Terms & Conditions. Any use of this article, must conform to the terms of that license which are available at http://pubs.acs.org.
###end p 4
###begin p 5
40.75
###end p 5
###begin p 6
###xml 0 0 0 0 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="jm-2008-01475n_0004" id="tgr1"/>

###end p 6
###begin p 7
###xml 242 243 242 243 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 251 252 251 252 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 394 410 394 410 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 417 419 417 419 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 693 695 693 695 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 791 793 791 793 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 853 855 853 855 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 899 900 899 900 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 900 901 900 901 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">D</sub>
###xml 394 410 <span type="species:ncbi:562">Escherichia coli</span>
The nonmevalonate route to isoprenoid biosynthesis is essential in Gram-negative bacteria and apicomplexan parasites. The enzymes of this pathway are absent from mammals, contributing to their appeal as chemotherapeutic targets. One enzyme, 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase (IspF), has been validated as a target by genetic approaches in bacteria. Virtual screening against Escherichia coli IspF (EcIspF) was performed by combining a hierarchical filtering methodology with molecular docking. Docked compounds were inspected and 10 selected for experimental validation. A surface plasmon resonance assay was developed and two weak ligands identified. Crystal structures of EcIspF complexes were determined to support rational ligand development. Cytosine analogues and Zn2+-binding moieties were characterized. One of the putative Zn2+-binding compounds gave the lowest measured KD to date (1.92 +/- 0.18 muM). These data provide a framework for the development of IspF inhibitors to generate lead compounds of therapeutic potential against microbial pathogens.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 359 360 359 360 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fn1" ref-type="fn">a</xref>
###xml 360 361 360 361 <label xmlns:mml="http://www.w3.org/1998/Math/MathML">a</label>
###xml 496 498 496 498 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 500 516 500 516 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 601 602 601 602 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 610 611 610 611 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 661 662 661 662 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 670 671 670 671 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 704 705 704 705 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 713 714 713 714 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 748 750 748 750 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Mt</italic>
###xml 752 778 752 778 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Mycobacterium tuberculosis</italic>
###xml 821 823 821 823 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Pf</italic>
###xml 825 846 825 846 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium falciparum</italic>
###xml 361 879 361 879 <p xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="10">Abbreviations: AraCMP, cytosine arabinoside monophosphate; CDV, cidofovir; DMSO, dimethylsulfoxide; DOXP, 1-deoxyxylulose 5-phosphate; <italic>Ec</italic>, <italic>Escherichia coli</italic>; FLUC, 5-fluorocytidine; IspC, 1-deoxyxylulose 5-phosphate reductoisomerase; IspF, 2<italic>C</italic>-methyl-<sc>d</sc>-erythritol-2,4-cyclodiphosphate synthase; ME2P, 2<italic>C</italic>-methyl-<sc>d</sc>-erythritol-2-phosphate; MECDP, 2<italic>C</italic>-methyl-<sc>d</sc>-erythritol-2,4-cyclodiphosphate; <italic>Mt</italic>, <italic>Mycobacterium tuberculosis</italic>; MVA, mevalonate; PDB, Protein Data Bank; <italic>Pf</italic>, <italic>Plasmodium falciparum</italic>; SPR, surface plasmon resonance.</p>
###xml 360 879 360 879 <fn xmlns:mml="http://www.w3.org/1998/Math/MathML" id="fn1"><label>a</label><p textid="10">Abbreviations: AraCMP, cytosine arabinoside monophosphate; CDV, cidofovir; DMSO, dimethylsulfoxide; DOXP, 1-deoxyxylulose 5-phosphate; <italic>Ec</italic>, <italic>Escherichia coli</italic>; FLUC, 5-fluorocytidine; IspC, 1-deoxyxylulose 5-phosphate reductoisomerase; IspF, 2<italic>C</italic>-methyl-<sc>d</sc>-erythritol-2,4-cyclodiphosphate synthase; ME2P, 2<italic>C</italic>-methyl-<sc>d</sc>-erythritol-2-phosphate; MECDP, 2<italic>C</italic>-methyl-<sc>d</sc>-erythritol-2,4-cyclodiphosphate; <italic>Mt</italic>, <italic>Mycobacterium tuberculosis</italic>; MVA, mevalonate; PDB, Protein Data Bank; <italic>Pf</italic>, <italic>Plasmodium falciparum</italic>; SPR, surface plasmon resonance.</p></fn>
###xml 882 883 882 883 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref1">1</xref>
###xml 939 940 939 940 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref2">2</xref>
###xml 941 942 941 942 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref4">4</xref>
###xml 939 942 939 942 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref2">2</xref>&#8722;<xref ref-type="bibr" rid="ref4">4</xref></sup>
###xml 1059 1060 1059 1060 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref4">4</xref>
###xml 1061 1062 1061 1062 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref6">6</xref>
###xml 1059 1062 1059 1062 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref4">4</xref>&#8722;<xref ref-type="bibr" rid="ref6">6</xref></sup>
###xml 1128 1129 1128 1129 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref4">4</xref>
###xml 1223 1224 1223 1224 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref6">6</xref>
###xml 1260 1261 1260 1261 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref7">7</xref>
###xml 1368 1390 1368 1390 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Prototheca wickerhamii</italic>
###xml 1391 1392 1391 1392 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref8">8</xref>
###xml 1398 1412 1398 1412 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium sp.</italic>
###xml 1413 1414 1413 1414 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref4">4</xref>
###xml 1415 1416 1415 1416 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref9">9</xref>
###xml 1550 1551 1550 1551 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref4">4</xref>
###xml 1664 1690 1664 1690 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Mycobacterium tuberculosis</italic>
###xml 1695 1716 1695 1716 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium falciparum</italic>
###xml 1779 1780 1779 1780 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref9">9</xref>
###xml 1781 1783 1781 1783 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref12">12</xref>
###xml 1779 1783 1779 1783 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref9">9</xref>&#8722;<xref ref-type="bibr" rid="ref12">12</xref></sup>
###xml 1887 1888 1887 1888 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref4">4</xref>
###xml 1889 1891 1889 1891 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref10">10</xref>
###xml 1892 1894 1892 1894 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref12">12</xref>
###xml 1895 1897 1895 1897 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref13">13</xref>
###xml 1887 1897 1887 1897 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref4">4</xref>,<xref ref-type="bibr" rid="ref10">10</xref>,<xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref13">13</xref></sup>
###xml 2099 2101 2099 2101 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref11">11</xref>
###xml 2102 2104 2102 2104 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref14">14</xref>
###xml 2099 2104 2099 2104 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup>
###xml 2168 2169 2168 2169 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 2177 2178 2177 2178 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 2279 2280 2279 2280 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 2288 2289 2288 2289 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 2340 2341 2340 2341 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">1</xref>
###xml 2344 2346 2344 2346 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref15">15</xref>
###xml 2431 2433 2431 2433 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
###xml 2434 2436 2434 2436 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref25">25</xref>
###xml 2431 2436 2431 2436 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref16">16</xref>&#8722;<xref ref-type="bibr" rid="ref25">25</xref></sup>
###xml 2573 2575 2570 2572 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
###xml 2576 2578 2573 2575 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref18">18</xref>
###xml 2573 2578 2570 2575 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref16">16</xref>&#8722;<xref ref-type="bibr" rid="ref18">18</xref></sup>
###xml 2627 2629 2624 2626 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2678 2679 2675 2676 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 2687 2688 2684 2685 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 2774 2776 2771 2773 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2782 2784 2779 2781 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2882 2884 2872 2874 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 2935 2937 2925 2927 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
###xml 2938 2940 2928 2930 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref18">18</xref>
###xml 2935 2940 2925 2930 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref18">18</xref></sup>
###xml 3029 3038 3019 3028 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">in silico</italic>
###xml 3112 3114 3102 3104 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 3148 3155 3138 3145 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 3162 3164 3152 3154 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 3183 3185 3173 3175 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
###xml 3341 3343 3331 3333 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref26">26</xref>
###xml 3548 3550 3538 3540 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 420 423 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
###xml 500 516 <span type="species:ncbi:562">Escherichia coli</span>
###xml 752 778 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
###xml 825 846 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 1192 1202 <span type="species:ncbi:3197">liverworts</span>
###xml 1368 1390 <span type="species:ncbi:3111">Prototheca wickerhamii</span>
###xml 1574 1580 <span type="species:ncbi:9606">humans</span>
###xml 1664 1690 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
###xml 1695 1716 <span type="species:ncbi:5833">Plasmodium falciparum</span>
###xml 3148 3155 <span type="species:ncbi:562">E. coli</span>
All isoprenoids are derived from two precursors, dimethylallyl diphosphate and isopentenyl diphosphate. The biosynthesis of these simple five-carbon compounds, which contribute to a plethora of important metabolites and natural products, is an important area of chemical biology. The precursors are either synthesized via the classical mevalonate pathway (MVAaaAbbreviations: AraCMP, cytosine arabinoside monophosphate; CDV, cidofovir; DMSO, dimethylsulfoxide; DOXP, 1-deoxyxylulose 5-phosphate; Ec, Escherichia coli; FLUC, 5-fluorocytidine; IspC, 1-deoxyxylulose 5-phosphate reductoisomerase; IspF, 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase; ME2P, 2C-methyl-d-erythritol-2-phosphate; MECDP, 2C-methyl-d-erythritol-2,4-cyclodiphosphate; Mt, Mycobacterium tuberculosis; MVA, mevalonate; PDB, Protein Data Bank; Pf, Plasmodium falciparum; SPR, surface plasmon resonance. )(1) or the more recently discovered nonmevalonate pathway.2-4 The MVA pathway is present in animals, fungi, the cytoplasm of phototrophic organisms, some eubacteria, and archaea,4-6 whereas the nonmevalonate pathway is present in most eubacteria,(4) in the chloroplasts of phototrophic organisms such as algae, liverworts, and higher plants,(6) and in cyanobacteria and diatoms.(7) It is also found in unicellular eukaryotes with an evolutionary linkage to photosynthetic phyla, such as Prototheca wickerhamii(8) and Plasmodium sp.(4,9) On the basis of chemical and genetic data, the enzymes of the nonmevalonate pathway are deemed attractive chemotherapeutic targets.(4) They are absent from humans and occur in many of the world's most serious pathogenic microorganisms, including Mycobacterium tuberculosis and Plasmodium falciparum, the causal agents for tuberculosis and malaria, respectively.9-12 There are seven enzymes in the pathway, and gene knockouts indicate that all are essential in bacteria.4,10,12,13 Such genetic validation is complemented by the chemical validation of 1-deoxyxylulose 5-phosphate (DOXP) reductoisomerase (IspC), the second enzyme in the pathway, using the antimicrobial fosmidomycin.11,14 The subject of this study is the fifth enzyme in the pathway, 2C-methyl-d-erythritol-2,4-cyclodiphosphate (MECDP) synthase, or IspF. This enzyme converts 4-diphosphocytidyl-2C-methyl-d-erythritol-2-phosphate into MECDP and CMP (Figure 1).(15) Structural and biochemical studies of IspF from several species have been reported.16-25 IspF forms a homotrimer built around a beta prism with three active sites, each of which is formed in a cleft between pairs of subunits.16-18 The active site comprises a rigid, nucleotide-Zn2+-binding pocket and a flexible loop to bind the 2C-methyl-d-erythritol-2-phosphate (ME2P) fragment of the substrate. A second divalent cation (Mg2+ or Mn2+), positioned between the alpha- and beta-phosphates of the substrate, acts in concert with the Zn2+ to align and polarize the substrate for catalysis.16,18 We have adopted a structure-based approach to identify inhibitors of IspF and screened, in silico, a database of commercially available compounds against the nucleotide-Zn2+-binding pocket. The structure of E. coli IspF (EcIspF) bound to CDP(16) was used to identify features considered important for ligand binding and affinity. A hierarchical filtering methodology and molecular docking with FlexX(26) generated several hits, which were then verified with X-ray crystallography and a surface plasmon resonance (SPR) assay. In addition, a more focused set of compounds was used to probe the cytidine and Zn2+-binding sites, yielding a ligand with low micromolar binding affinity.
###end p 9
###begin p 10
###xml 135 137 135 137 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 139 155 139 155 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 240 241 240 241 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 249 250 249 250 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 300 301 300 301 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 309 310 309 310 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 343 344 343 344 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 352 353 352 353 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 387 389 387 389 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Mt</italic>
###xml 391 417 391 417 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Mycobacterium tuberculosis</italic>
###xml 460 462 460 462 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Pf</italic>
###xml 464 485 464 485 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Plasmodium falciparum</italic>
###xml 59 62 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
###xml 139 155 <span type="species:ncbi:562">Escherichia coli</span>
###xml 391 417 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
###xml 464 485 <span type="species:ncbi:5833">Plasmodium falciparum</span>
Abbreviations: AraCMP, cytosine arabinoside monophosphate; CDV, cidofovir; DMSO, dimethylsulfoxide; DOXP, 1-deoxyxylulose 5-phosphate; Ec, Escherichia coli; FLUC, 5-fluorocytidine; IspC, 1-deoxyxylulose 5-phosphate reductoisomerase; IspF, 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase; ME2P, 2C-methyl-d-erythritol-2-phosphate; MECDP, 2C-methyl-d-erythritol-2,4-cyclodiphosphate; Mt, Mycobacterium tuberculosis; MVA, mevalonate; PDB, Protein Data Bank; Pf, Plasmodium falciparum; SPR, surface plasmon resonance.
###end p 10
###begin p 11
The reaction catalyzed by IspF.
###end p 11
###begin title 12
Results and Discussion
###end title 12
###begin title 13
Protein Structure Selection
###end title 13
###begin p 14
###xml 272 285 272 285 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">P. falciparum</italic>
###xml 287 289 287 289 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Pf</italic>
###xml 299 314 299 314 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">M. tuberculosis</italic>
###xml 316 318 316 318 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Mt</italic>
###xml 361 363 361 363 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 454 456 454 456 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 736 738 736 738 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 744 746 744 746 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Pf</italic>
###xml 756 758 756 758 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Mt</italic>
###xml 903 904 903 904 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">2</xref>
###xml 906 908 906 908 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
###xml 909 911 909 911 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref21">21</xref>
###xml 906 911 906 911 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref21">21</xref></sup>
###xml 1008 1010 1008 1010 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 272 285 <span type="species:ncbi:5833">P. falciparum</span>
###xml 299 314 <span type="species:ncbi:1773">M. tuberculosis</span>
The selection of the protein structure to provide the template for ligand discovery is critical because the performance of molecular docking depends on the conformation of the active site residues of the target. Although our ultimate interest is to discover inhibitors of P. falciparum (PfIspF) and M. tuberculosis (MtIspF), these structures are not known, and EcIspF was selected as the template for virtual screening based on a number of criteria. The EcIspF enzyme is the best characterized following detailed biochemical analyses and with high resolution crystal structures available of the enzyme bound to a number of ligands including the substrate and product. There is high overall sequence homology between the active sites of EcIspF, PfIspF, and MtIspF. The residues that coordinate the two divalent cations are conserved, as are the residues that interact directly with the substrate (Figure 2).16,21 In addition, the established protocols for overexpression, purification, and crystallization of EcIspF facilitated experimental validation of putative ligands.
###end p 14
###begin p 15
###xml 32 39 32 39 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 41 56 41 56 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">M. tuberculosis</italic>
###xml 90 103 90 103 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">P. falciparum</italic>
###xml 140 142 140 142 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 249 251 242 244 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 439 441 432 434 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 470 472 463 465 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 476 478 469 471 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 32 39 <span type="species:ncbi:562">E. coli</span>
###xml 41 56 <span type="species:ncbi:1773">M. tuberculosis</span>
###xml 90 103 <span type="species:ncbi:5833">P. falciparum</span>
Sequence alignment of IspF from E. coli, M. tuberculosis, and the catalytic domain of the P. falciparum protein. The secondary structure of EcIspf is depicted as purple arrows for beta-strands, yellow cylinders for alpha-helices, red cylinders for 310-helices. Residues whose identity is strictly conserved in all three sequences are boxed in black, conservative substitutions in gray. Grey triangles mark three residues that coordinate Zn2+, and an open triangle the Mg2+/Mn 2+-binding Glu-135. Circles mark CDP-binding residues (open and filled to distinguish subunits). The highly conserved segment leading into a1 forms the ME2P binding site.
###end p 15
###begin p 16
###xml 201 203 201 203 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 372 374 372 374 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 519 521 519 521 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 573 575 573 575 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 823 825 823 825 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 840 842 840 842 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 908 910 908 910 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 955 957 955 957 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
We decided to concentrate efforts on the cytidine-binding pocket. This section offers a relatively static part of the active site in comparison to the ME2P-binding pocket. Twelve crystal structures of EcIspF were available, and selection criteria were applied to select one for virtual screening. Structures that did not contain a ligand were eliminated and because the Zn2+-binding site comprised part of the target, structures without this cation were also discarded. The remaining choices were complex structures of EcIspF bound to CMP, CDP, or product (CMP and MECDP). EcIspF-CMP complexes were eliminated because CMP is a substructure of the CDP and product complexes. In some instances, redundant complexes were present and the highest resolution structure was selected. At the end of this process, two structures of EcIspF remained: EcIspF-CDP (Protein Data Bank (PDB) code , at 1.8 A resolution) and EcIspF-CMP-MECDP (PDB , 2.3 A resolution). The EcIspF-CDP structure was chosen by virtue of the higher resolution of the analysis.
###end p 16
###begin title 17
Validation of FlexX with EcIspF for Virtual Screening
###end title 17
###begin p 18
###xml 58 60 58 60 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref26">26</xref>
###xml 151 153 151 153 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 599 601 599 601 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref27">27</xref>
It was first necessary to assess the suitability of FlexX(26) for our modeling, and it was used to generate binding modes of CDP in the active site of EcIspF. FlexX can apply two scoring functions, F-Score and DrugScore, to rank binding modes, and both were evaluated. In addition, the quality of each binding pose was assessed by the root mean squared deviation (rmsd) of atomic positions between the calculated and experimentally determined binding modes. The ligand poses that are generated are defined as "well-docked" if they display an rmsd of less than 2.0 A from the experimental structure.(27) When CDP was docked back into the active site of , only 70% of the top 20 poses ranked by F-Score had rmsd values significantly less than this threshold value compared to 100% by DrugScore. The closest generated pose, which was ranked ninth by DrugScore, was within 0.6 A of the experimental conformation (data not shown). These results demonstrate the suitability of FlexX/DrugScore and the applied docking protocol for this enzyme.
###end p 18
###begin title 19
Hierarchical Filtering and Virtual Screening
###end title 19
###begin p 20
###xml 135 137 135 137 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref28">28</xref>
###xml 138 140 138 140 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref29">29</xref>
###xml 135 140 135 140 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref28">28</xref>,<xref ref-type="bibr" rid="ref29">29</xref></sup>
###xml 392 394 392 394 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref30">30</xref>
###xml 410 412 410 412 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref31">31</xref>
###xml 661 663 661 663 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 669 671 669 671 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
###xml 711 712 711 712 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">3</xref>
###xml 954 955 954 955 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">3</xref>
###xml 988 990 988 990 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 1146 1147 1146 1147 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">3</xref>
###xml 1240 1242 1240 1242 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 1477 1479 1477 1479 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 1600 1601 1600 1601 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1" ref-type="table">1</xref>
We adopted a three-step hierarchical filtering approach, removing compounds based on molecular complexity, topology, and functionality.28,29 Initially, filters were applied to a database of approximately 1 million commercially available compounds so that only those with less than seven rotatable bonds and a molecular mass below 450 Da were retained. These criteria are based on theoretical(30) and empirical(31) arguments, suggesting that lead compounds should be of limited complexity to allow for subsequent lead optimization. In the second step, a three-dimensional pharmacophore hypothesis was constructed based on the interactions formed between CDP and EcIspF.(16) This pharmacophore hypothesis (Figure 3) was composed of a hydrophobic component (H), centered on the pyrimidine of CDP, a hydrogen bond donor group (D1) based on the exocyclic amine group, and two hydrogen bond acceptor groups derived from N3 (A2) and O2 (A3) of cytosine (Figure 3). The hydrogen bond partners on EcIspF that complement the pharmacophore are the hydroxyl group of Thr133 (A1) and the main chain amides of Met103 (D2) and Leu106 (D3), respectively (Figure 3). The pharmacophore filtering procedure selected 4063 compounds, which were docked into the EcIspF active site. Spatial constraints of 1.0 A for the hydrophobic feature and 0.7 A for donor and acceptor features were applied in order to match the same type of chemical interactions of potential ligands with those observed in the EcIspF-CDP complex. The top 250 hits were inspected visually, and 10 compounds selected for experimental validation (Table 1) based on a number of criteria. It was judged important that there was a complementarity of the ligand and protein surfaces, reasonable internal geometry of the ligand in the binding pose, proximity of the hydrophobic center of the ligand to the cytosine binding pocket, and that reasonable hydrogen bonding interactions, typically with the separation of donor and acceptor groups in the range 2.4-3.5 A, were predicted.
###end p 20
###begin p 21
###xml 47 49 47 49 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 121 123 121 123 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 144 146 144 146 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 199 201 199 201 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
The pharmacophore hypothesis for inhibition of EcIspF. CDP is shown as a stick model together with the two metal ions (Mn2+ purple sphere and Zn2+ gray sphere) and key residues in the active site of EcIspF. Atoms are colored C cyan, N blue, O red, P orange, S yellow. The large red spheres mark hydrogen bond accepting groups of the ligand (A1 and A2) and the protein (A3-1 and A3-2), the blue spheres mark hydrogen bond donor sites on the protein (D1, D2) and the ligand (D3), and the green sphere identifies the hydrophobic component centered on the pyrimidine ring.
###end p 21
###begin title 22
###xml 54 55 54 55 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1-fn1" ref-type="table-fn">a</xref>
Potential IspF Ligands Identified by Virtual Screeninga
###end title 22
###begin p 23
###xml 9 11 9 11 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 75 76 75 76 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 226 227 226 227 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 229 231 229 231 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 237 238 237 238 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
Compound 6b was not identified by virtual screening but is a derivative of 6 likely generated following hydrolysis and was identified following the crystal structure determination (see text). The ribose rings are numbered for 6, 6b, and 7. n.d. = not determined.
###end p 23
###begin title 24
Binding Affinities of Compounds to EcIspF
###end title 24
###begin p 25
###xml 30 32 30 32 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 59 60 59 60 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">4</xref>
###xml 140 141 140 141 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1" ref-type="table">1</xref>
###xml 657 658 656 657 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 663 664 662 663 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 703 704 702 703 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 704 705 703 704 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">D</sub>
###xml 806 807 805 806 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 812 813 811 812 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 839 840 838 839 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 840 841 839 840 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">D</sub>
An SPR assay with immobilized EcIspF was developed (Figure 4) in order to determine the binding affinities of the selected compounds (Table 1). Five of these compounds required significant concentrations of dimethyl sulfoxide (DMSO) in order to dissolve, compromising the use of SPR. Consequently, binding for five of the compounds was analyzed. A series of concentrations of each compound ranging from 0.1 muM to 10 mM were applied for the assay. The binding responses were recorded as a function of time and, at all compound concentrations, the responses reached equilibrium and dissociated rapidly, indicating that binding was reversible. Only compounds 6 and 7 yielded quantifiable data. Values for KD were obtained by fitting the steady-state binding curves to a 1:1 Langmuir binding model. Compounds 6 and 7 are weak ligands, having KD values of 20.5 +/- 2.23 and 0.925 +/- 0.71 mM, respectively. The binding affinities of CMP (0.903 +/- 0.107 mM) and CDP (0.097 +/- 0.006 mM) were also determined, for the first time, for reference.
###end p 25
###begin p 26
###xml 84 86 84 86 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 239 241 227 229 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 337 339 325 327 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 526 527 514 515 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1061 1062 1039 1040 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 1062 1063 1040 1041 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sub>
Representative binding sensorgrams of CDP (a) and CMP (b) to covalently immobilized EcIspF. Reference-corrected SPR binding curves for various concentrations of CDP and CMP monitored on a surface with approximately5000 RU of amine coupled EcIspF. The data were globally fitted using a kinetic model where a 1:1 complex is formed between EcIspF and CDP or CMP. The small graphs show the steady state (equilibrium) RU after fitting vs the concentrations of CDP or CMP. Running buffer was 50 mM sodium phosphate (pH 7), 2 mM MgCl2 and 0.005% surfactant P20. In graph (a), curve a = 25 muM CDP; b = 50 muM CDP; c = 100 muM CDP; d = 200 muM CDP; e = 400 muM CDP; f = 800 muM CDP; g = 1.6 mM CDP. In graph (b), curve a = 78.1 muM CMP; b = 156.2 muM CMP; c = 312.5 muM CMP; d = 625 muM CMP; e = 1.25 mM CMP; f = 2.5 mM CMP; g = 5 mM CMP. Insets in (a) and (b): Nonlinear steady-state affinity analysis for the corresponding interaction. The curve drawn is the best-fit curve to a single-site binding equation with the program GraphPad Prism. This provides an apparent Kd of 96.59 +/- 6.45 muM for CDP and 903.63 +/- 10.77 muM for CMP.
###end p 26
###begin p 27
###xml 10 12 10 12 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 57 58 57 58 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 63 64 63 64 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 76 77 76 77 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 82 83 82 83 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 260 262 254 256 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 313 315 307 309 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 380 381 374 375 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 386 387 380 381 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 398 399 392 393 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 399 400 393 394 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">D</sub>
###xml 404 405 398 399 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 440 441 434 435 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 515 517 509 511 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
CDP binds EcIspF at least 10-fold more tightly than CMP, 6, or 7. Compounds 6 and 7 are both CMP analogues and, like CMP, lack a beta-phosphate. This suggests a significant contribution of the beta-phosphate to ligand affinity, and we note in the structure of EcIspF that this group coordinates the active site Zn2+. Despite their structural similarity, the binding affinities of 6 and 7 vary. The KD of 7 is comparable to that of CMP, but 6 binds about 20-fold weaker. Crystal structures of these ligands bound to EcIspF were determined to investigate this observation.
###end p 27
###begin title 28
Structural Characterization of Active Compounds
###end title 28
###begin p 29
###xml 21 23 21 23 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 43 44 43 44 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 49 50 49 50 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 130 131 130 131 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl2" ref-type="table">2</xref>
###xml 253 254 253 254 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 320 322 320 322 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 330 331 330 331 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1" ref-type="table">1</xref>
###xml 489 491 489 491 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 622 624 622 624 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 812 814 808 810 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 819 820 815 816 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 980 982 972 974 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
###xml 983 985 975 977 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref18">18</xref>
###xml 980 985 972 977 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref16">16</xref>,<xref ref-type="bibr" rid="ref18">18</xref></sup>
Cocrystallization of EcIspF with compounds 6 and 7 gave crystals that diffracted to 3.1 and 2.7 A resolution, respectively (Table 2). However, the observed electron and difference density maps suggested that hydrolysis has occurred at the ribose O2' of 6, producing a nonbridging phosphate at the 3' position; therefore 6b (Table 1) was modeled and refined satisfactorily. For discussion purposes, the experimental ligand and protein active site conformations are compared to CDP bound to EcIspF (PDB ) because this provided the template for docking. As predicted, the compounds bind within the cytidine-binding pocket of EcIspF. There are no major conformational changes in the enzyme upon ligand binding as evidenced by the rmsd differences (0.33, 0.29 A) between Calpha atoms of the compound-enzyme complexes 6b and 7 with . The largest Calpha rmsd differences occur in the flexible loop (residues 62-71) that binds ME2P. This loop is poorly ordered in the absence of a ligand.16,18
###end p 29
###begin title 30
###xml 45 47 45 47 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
Data Processing and Refinement Statistics of EcIspF Ligand Complexes
###end title 30
###begin p 31
As reported in SCALA, including partials.
###end p 31
###begin p 32
Values in parentheses refer to the highest resolution shell of about 0.1 A width.
###end p 32
###begin p 33
a.u. = asymmetric unit.
###end p 33
###begin p 34
###xml 9 10 9 10 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 127 128 127 128 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1" ref-type="table">1</xref>
###xml 198 199 198 199 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 265 266 265 266 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">5</xref>
###xml 398 399 395 396 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 538 540 535 537 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
###xml 673 674 670 671 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">5</xref>
###xml 855 856 852 853 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 875 877 872 874 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 1176 1177 1173 1174 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 1272 1274 1269 1271 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
Compound 7 comprises a cytosine, ribose, and phosphate similar to CMP, but the phosphate bridges ring positions 3 and 4 (Table 1). Despite this difference, a structural comparison demonstrates that 7 resembles the CMP fragment of CDP in its mode of binding (Figure 5); all protein ligand interactions are maintained except for those involving the beta-phosphate of CDP, which has no counterpart in 7. The cytosine moieties of both ligands bind, forming a network of interactions to main chain atoms of Ala100, Met104, Met105, and Leu106.(16) We note the possibility that a bifurcated hydrogen bond is formed between the amide of Met103 and the pyrimidine N3 and O2 (Figure 5a). The ligand O2' hydroxyl forms hydrogen bonds to the carboxylate of Asp56 from one subunit and water-mediated hydrogen bonds to the amide of Ala131 of a second subunit. Compound 7 interactions with EcIspF vary from those of CDP in that the phosphate binds the side chain hydroxyl of Thr133 through a water-mediated interaction rather than a direct interaction, and there is an additional water-mediated hydrogen bond linkage to the main chain carbonyl of Phe61. The comparable binding affinities of 7 and CMP are clearly due to their chemical similarity and equivalent binding interactions with EcIspF.
###end p 34
###begin p 35
###xml 0 2 0 2 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 44 46 44 46 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 71 72 71 72 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 78 80 78 80 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 110 111 110 111 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 141 143 141 143 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 185 186 185 186 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 195 197 195 197 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 210 212 210 212 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 217 218 217 218 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 240 241 240 241 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 241 242 241 242 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 245 246 245 246 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 246 247 246 247 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 363 365 359 361 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 739 740 735 736 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 797 799 793 795 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
EcIspF-ligand complexes. The active site of EcIspF in complex with (a) 7, (b) 6b, (c) superposition of CDP on 7, (d) superposition of CDP on 6b, and (e) superposition of the top docked 7 pose in EcIspF-CDP and EcIspF-7. In (a) and (b), the Fo - Fc omit map contoured at 3sigma and colored green is shown and black dashed lines indicate putative hydrogen bonds. Zn2+ and water molecules are represented as gray and blue spheres, respectively, and the gray dashed lines represent metal ion ligand coordination. Protein residues labeled with a prime indicate that they belong to a partner subunit. Atoms are colored as followed: C atoms of the protein are cyan, N blue, O red, S yellow, P orange, ligand C atoms are black, and CDP and docked 7 C atoms are gray. In (e), C atoms of the protein in the EcIspF-CDP complex are gray.
###end p 35
###begin p 36
###xml 9 10 9 10 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 233 234 233 234 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl1" ref-type="table">1</xref>
###xml 246 247 246 247 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 377 379 374 376 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 398 399 395 396 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">5</xref>
###xml 660 662 653 655 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 667 669 660 662 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 764 766 757 759 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 777 779 770 772 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 1025 1027 1018 1020 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 1078 1079 1071 1072 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">5</xref>
###xml 1105 1107 1098 1100 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 1148 1150 1141 1143 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1274 1276 1267 1269 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1309 1311 1302 1304 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
###xml 1330 1332 1323 1325 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
Compound 6 was selected to probe the specificity of the binding pocket for different sugars as well as phosphate placement. This compound contains a cytosine and a lyxose with a phosphate bridging the 2 and 3 ribose positions (Table 1). Compound 6 was supplied as a mixture of anomers, but the experimental density suggested that only the beta-anomer of the hydrolysis product 6b has bound (Figure 5b). Steric clash between the alpha-anomer O5' and side chains of Asp56 or Leu106 is the likely explanation for this observation. Despite this unexpected modification to the purchased compound, the network of interactions between the cytosine moiety of compound 6b and EcIspF is similar to that observed in the complex with CDP. The binding interactions between the 6b sugar and EcIspF resemble those observed between the ribose of CDP and the enzyme. The O2' and O4' groups of both sugars form hydrogen bonds with the side chains of Asp56 and Lys104, respectively. The orientation and interactions of the phosphates in C7 and 6b, however, vary from those observed in CDP (Figure 5c,d). In the complex with 6b, the phosphate is directed toward the Zn2+-binding site rather than forming a hydrogen bond to the Thr132 side chain hydroxyl and an electrostatic interaction with Mn2+ as observed in the CDP complex.(16) The phosphate of 6b forms solvent-mediated hydrogen bonds with the side chains of Asp46, Asp56, Thr132, and Thr133, the amide of Gly58, and the carbonyl of Ala131. The effects on binding affinity of replacing ribose with lyxose and changing the phosphorylation site are indeterminable because the relative quantities of the anomers and the amount of hydrolyzed ligand, present under assay conditions, are unknown.
###end p 36
###begin title 37
Comparison of Predicted vs Experimental Binding Modes
###end title 37
###begin p 38
###xml 338 339 338 339 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 488 489 488 489 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 527 529 527 529 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 554 555 554 555 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">5</xref>
###xml 940 941 938 939 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 1324 1325 1322 1323 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">5</xref>
Comparison of models obtained by the computational docking approach with structures determined by X-ray crystallography give an indication of how reliable predictive modeling can be for a specific system and may suggest where receptor/target flexibility or inflexibility can affect ligand binding. The predicted and experimental poses of 7 have an rmsd difference of 0.92 A. The predicted interactions between the protein and the cytosine moiety of the top ranked binding conformation of 7 are similar to those observed in the EcIspF-CDP complex (Figure 5e), but the binding interactions of the ligand sugar and phosphate with the protein differ due to side chain movements, changes in the flexible ME2P-binding loop, and slight differences in ligand conformation and placement (data not shown). In the docked complex, a phosphate oxygen and O5' are 2.9 and 2.5 A from CD1 of Ile57 and the side chain of Asp63. In the crystal structure, chi1 of Ile57 has changed so that CD1 is shifted away from the ligand phosphate, the Asp63 side chain has adjusted position, and the ligand is displaced from the predicted binding site by approximately 0.6 A to alleviate these close contacts (data not shown). The crystal structure also identifies a shift in the side chain of Lys104 to form a hydrogen bond to O4' of the ligand (Figure 5b), an interaction not predicted in the modeled complex.
###end p 38
###begin p 39
###xml 25 27 25 27 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 50 52 50 52 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 124 125 124 125 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 281 282 281 282 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
We did not dock compound 6b in the active site of EcIspF. In this case, the ligand has resulted from hydrolysis of compound 6, which had been docked previously. Comparisons indicated that the position of the cytosine moieties agreed to the same extent as seen for comparisons with 7 (data not shown).
###end p 39
###begin title 40
Analysis of Cytosine Analogues
###end title 40
###begin p 41
###xml 174 176 174 176 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 547 549 547 549 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref32">32</xref>
###xml 620 622 620 622 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Our aim is to obtain ligand scaffolds and through appropriate structural modifications to improve binding affinities. However, with limited structural diversity of potential EcIspF ligands identified through virtual screening, in essence a single chemotype, it was decided to rationally select compounds to investigate the binding properties of part of the active site. Fluorescent substrate analogues have been used to examine the flexible loop that binds the substrate fragment ME2P and how this loop adjusts to a variety of aromatic scaffolds.(32) Here, we restricted our investigation to probing the cytidine- and Zn2+-binding sites using cytosine analogues and common metal ion binding moieties, respectively. Both sets of compounds represent potential building blocks with beneficial pharmacokinetic properties and scope for optimization.
###end p 41
###begin p 42
###xml 401 402 401 402 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl3" ref-type="table">3</xref>
###xml 465 467 465 467 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref33">33</xref>
###xml 468 470 468 470 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref34">34</xref>
###xml 465 470 465 470 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref33">33</xref>,<xref ref-type="bibr" rid="ref34">34</xref></sup>
###xml 524 526 524 526 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 588 589 588 589 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl2" ref-type="table">2</xref>
###xml 664 665 664 665 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl3" ref-type="table">3</xref>
###xml 1240 1241 1236 1237 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">6</xref>
###xml 1412 1414 1408 1410 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
###xml 1486 1487 1482 1483 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">6</xref>
###xml 132 135 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
###xml 416 419 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
###xml 515 518 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
###xml 1064 1067 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
###xml 1434 1437 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
Three compounds were selected to investigate how small modifications to the ribose and cytosine moieties affect binding. Cidofovir (CDV), cytosine arabinoside monophosphate (AraCMP), and 5-fluorocytidine (FLUC) were chosen to probe the effects, respectively, of removing the sugar, altering chirality at C2', and of whether a particular covalent modification on the cytosine ring was tolerated (Table 3). AraCMP and CDV are drugs used in cancer and viral therapies.33,34 The complex structures of AraCMP, FLUC, and CDV with EcIspF were determined to 2.1, 2.5, and 2.8 A resolution (Table 2), respectively, and ligand binding affinities determined using SPR (Table 3). Most of the protein residues are well defined in the electron density maps for all structures except for residues 62-71, which form the flexible ME2P binding site and are poorly ordered. There are no major conformational changes upon ligand binding, as evidenced by the rmsd differences of 0.27, 0.36, and 0.25 A for the overlay of Calpha atoms of the compound-enzyme complexes FLUC, AraCMP, and CDV, respectively, with the CDP complex, PDB code . The crystal structures of the complexes confirm that the ligands are firmly anchored in the cytidine-binding pocket (Figure 6). The cytosine moiety of each ligand forms the same network of interactions to the main chain of Ala100, Lys104, Met105, and Leu106, as observed in the complex with CDP.(16) AraCMP, FLUC, and CDV bind in a similar manner to CMP and CDP (Figure 6).
###end p 42
###begin title 43
###xml 20 21 20 21 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl3-fn1" ref-type="table-fn">a</xref>
Cytosine Derivativesa
###end title 43
###begin p 44
Ligand codes, names, structures, molecular weight, and binding affinities are given.
###end p 44
###begin p 45
###xml 36 38 36 38 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 63 65 63 65 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 139 140 139 140 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 140 141 140 141 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">o</sub>
###xml 144 145 144 145 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">F</italic>
###xml 145 146 145 146 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sub>
###xml 250 251 246 247 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">5</xref>
###xml 116 119 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
###xml 174 181 <span type="species:ncbi:9031">chicken</span>
Cytosine-based compounds binding to EcIspF. The active site of EcIspF in complex with (a) AraCMP, (b) FLUC, and (c) CDV. In each case, the Fo - Fc omit map is shown as green chicken wire and contoured at 3sigma. The color scheme is similar to Figure 5.
###end p 45
###begin p 46
###xml 27 29 27 29 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 201 202 201 202 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">6</xref>
###xml 371 373 371 373 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 864 866 864 866 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
The asymmetric unit of the EcIspF-AraCMP complex crystal structure contains six subunits. Five of the active sites are occupied by ordered AraCMP molecules, and the protein-ligand interactions (Figure 6a) are identical in each case. To prevent steric clash of the O2' hydroxyl with Asp56 and Ala131, the cytosine moiety of AraCMP moves slightly away from the backbone of EcIspF compared to the CMP fragment of CDP (data not shown). This allows the formation of a hydrogen bond between O2' and the carbonyl of Ala131. O2' also participates in a water-mediated interaction to the amide of Ala131. The O3' group forms a water-mediated hydrogen bond with the amide of Gly58. This is in contrast to the interactions made by the O2' and O3' groups of CDP, which both form direct hydrogen bonds to the side chain of Asp56 and, for the latter only, to the amide of Gly58.(16) Like the CMP fragment of CDP, the phosphate group of AraCMP interacts with side chain and main chain atoms of Thr132 and Thr133. Overall, AraCMP forms between 8 and 9 direct hydrogen bonds compared to 10-11 formed by CMP. AraCMP has a binding affinity of 18.9 +/- 5.8 mM, which is 20-fold weaker than CMP (0.903 +/- 0.107 mM). Although the active site can accommodate a change in chirality at C2', this is accompanied by a large, unfavorable effect on binding affinity.
###end p 46
###begin p 47
###xml 92 93 92 93 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">6</xref>
###xml 1169 1171 1157 1159 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
The same network of protein-pyrimidine interactions is observed in the FLUC complex (Figure 6b), although the cytosine pocket of the enzyme has expanded slightly to accommodate the additional substituent on the pyrimidine. The distance between the Calpha atoms of Thr133 and Leu106 of the same subunit defines one dimension of the enzyme active site and is slightly longer in the FLUC complex (12.5 A) compared to the CDP complex (11.9 A). In the FLUC complex, the cytosine moiety shifts closer to Met105 and Leu106 compared to the CDP complex, allowing the formation of a hydrogen bond between the fluorine and main chain amide of Thr133. In the CDP complex, the alpha-phosphate accepts a hydrogen bond from this amide group. The pyrimidine shift in the FLUC complex prevents O3' from interacting with the side chain of Asp56 and causes the side chain of Leu106 to shift away from the ligand to prevent steric clash. Although FLUC has no phosphate group, the binding affinity (2.02 +/- 0.42 mM) is similar to that of CMP (0.903 +/- 0.107 mM), implying that the fluorine atom compensates for the loss of phosphate-derived electrostatic interactions. Binding of FLUC by EcIspF suggests that additional pyrimidine substituents could be accommodated by the enzyme active site and further systematic investigation to determine the limits on the number, size, and chemical properties of additional substituents that can be accommodated are warranted.
###end p 47
###begin p 48
###xml 105 107 105 107 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
###xml 220 221 220 221 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">6</xref>
###xml 354 356 354 356 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 460 462 456 458 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 749 751 733 735 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 23 26 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
###xml 278 281 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
###xml 452 455 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
###xml 741 744 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
The cytosine moiety of CDV forms the same interactions with the protein as previously described for CDP,(16) which are the only direct interactions with the protein; all other hydrogen bonds are solvent-mediated (Figure 6c). The interactions between the noncytosine fragment of CDV and protein resemble those solvent-mediated interactions formed between EcIspF with the ribose and alpha-phosphate moieties of CDP. Solvent-mediated interactions between CDV and EcIspF include ligand phosphate associations with the side chains of Asp56, Asp63, Thr132, and the amides of Ala131 and Thr133. The lack of direct hydrogen bonding interactions between the ligand and enzyme probably contributes to the weak binding affinity (approximately40 mM) of CDV for EcIspF.
###end p 48
###begin title 49
###xml 14 16 14 16 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
Analysis of Zn2+-Binding Moieties
###end title 49
###begin p 50
###xml 58 60 58 60 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 78 80 78 80 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref35">35</xref>
###xml 103 104 103 104 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl4" ref-type="table">4</xref>
###xml 127 132 127 132 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">11&#8722;13</bold>
###xml 159 164 159 164 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">14&#8722;16</bold>
###xml 311 313 311 313 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 375 377 375 377 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 638 640 638 640 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">11</bold>
###xml 645 647 645 647 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">12</bold>
###xml 928 930 928 930 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">13</bold>
###xml 943 944 943 944 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 944 945 944 945 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">D</sub>
###xml 977 979 974 976 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">13</bold>
###xml 1075 1077 1072 1074 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1142 1144 1139 1141 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1174 1181 1171 1178 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 1383 1385 1380 1382 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 1406 1408 1402 1404 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref36">36</xref>
###xml 1460 1462 1456 1458 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1559 1561 1555 1557 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 1644 1646 1640 1642 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1840 1841 1836 1837 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">1</xref>
###xml 1859 1861 1855 1857 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1174 1181 <span type="species:ncbi:562">E. coli</span>
Hydroxamates and sulfonamides are among the most common Zn2+-binding ligands.(35) Six compounds (Table 4), three hydroxamates (11-13), and three sulfonamides (14-16), were selected for this study based on commercial availability and mass to ensure that the putative ligands were small enough to bind within the EcIspF active site. Cocrystallization of all six compounds with EcIspf was attempted, but, for reasons we cannot explain, no crystals were obtained. The sulfonamide compounds were only soluble in DMSO, thus hindering the SPR binding assay. The hydroxamates were soluble in assay buffer but no measurable data were obtained for 11 and 12, probably due to their small mass. The change in refractive index for binding of a ligand smaller than 180 Da is likely too small to be detected on a BiaCore 3000 instrument (John Butler, personal communication). The SPR binding assay was able to quantify the binding affinity of 13, yielding a KD of 1.92 +/- 0.18 muM. Compound 13 has the highest affinity of all the ligands examined in this study, and we attribute this to Zn2+-hydroxamate coordination. Similar observations apply to other Zn2+-dependent enzymes, including E. coli LpxC, an enzyme in the lipid A biosynthesis pathway. Kinetic studies of LpxC revealed that replacing a carboxylate group on 4,5 dihydro-2-phenyloxazole-4-carboxylic acid with hydroxamate lowered the IC50 from >400 to 3 muM.(36) Our observations suggest that the addition of a Zn2+-binding moiety may prove valuable in assisting the design of potent and selective inhibitors of EcIspF. In this, one possible strategy could be to develop molecules tethered by a Zn2+-binding moiety to the catalytic center, which then extend to the cytosine-binding pocket where very clear and conserved molecular features could assist the incorporation of specificity (Figure 1B). Because the Zn2+ location is within proximity of the ME2P binding site, then there is also the potential to extend from a metal-binding group using molecular fragments that mimic the methylerythritol component of substrate, a moiety that also interacts with a highly conserved part of the enzyme.
###end p 50
###begin title 51
###xml 55 56 55 56 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl4-fn1" ref-type="table-fn">a</xref>
Table of Selected Hydroxamate and Sulfonamide Compoundsa
###end title 51
###begin p 52
Ligand codes, names, structures, molecular weight (MW) and binding affinities are shown. n.d. = not determined.
###end p 52
###begin title 53
Ligand Efficiency to Compare Compounds
###end title 53
###begin p 54
###xml 52 54 52 54 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref32">32</xref>
###xml 82 84 82 84 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 271 273 271 273 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref37">37</xref>
###xml 465 467 461 463 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref38">38</xref>
###xml 514 517 510 513 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="eq1.1" ref-type="disp-formula">1.1</xref>
###xml 558 559 554 555 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 609 610 605 606 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl5" ref-type="table">5</xref>
###xml 620 632 616 624 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">&#916;G = &#8722;RT</italic>
###xml 636 637 628 629 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 637 638 629 630 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">d</italic>
###xml 637 638 629 630 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML"><italic>d</italic></sub>
###xml 643 644 635 636 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
Previously reported fluorescent substrate analogues(32) have greater affinity for EcIspF and a measurable gain in binding free enthalpy compared to the compounds in this study. Although potency is an important criterion for assessing lead compounds it can be misleading.(37) A useful parameter for assessing the potential of a weak lead for inhibitor design is to calculate the binding energy per non-hydrogen atom for each ligand, or 'ligand efficiency' (Deltag).(38) This parameter was calculated using equation 1.1 for the compounds in this study (except 6), and the substrate fragments CDP and CMP (Table 5).  where DeltaG = -RT ln Kd and N is the number of non-hydrogen atoms.
###end p 54
###begin title 55
Ligand Efficiency for Compounds Used in This Study
###end title 55
###begin p 56
###xml 33 35 33 35 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 103 105 103 105 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 139 141 139 141 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 280 282 280 282 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 397 399 397 399 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref32">32</xref>
###xml 453 455 453 455 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">13</bold>
###xml 499 500 495 496 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 522 524 518 520 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 679 681 675 677 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 695 697 691 693 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref38">38</xref>
Interestingly, FLUC (-0.81 kJ.mol-1/non-H atom) has a ligand efficiency comparable to CDP (-0.87 kJ.mol-1/non-H atom) and CMP (-0.79 kJ.mol-1/non-H atom). Although the fluorescent substrate analogues have greater potency, they have lower ligand efficiencies (-0.64 to -0.70 kJ.mol-1/non-H atom) compared to CMP. The aromatic moieties added to the substrate-like entities benefit binding affinity,(32) but they do not improve ligand efficiency. Compound 13 has the best ligand efficiency with a Deltag value of -2.04 kJ.mol-1/non-H atom. This is significantly improved over CDP yet much weaker in comparison to the average value associated with a drug in clinical use (-6.3 kJ.mol-1/non-H atom).(38)
###end p 56
###begin title 57
Conclusions
###end title 57
###begin p 58
###xml 58 60 58 60 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 371 373 371 373 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 478 480 478 480 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 743 746 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
In this study, virtual screening for potential ligands of EcIspF was performed exploiting a hierarchical filtering methodology followed by molecular docking with the program FlexX. Application of an SPR assay and crystallographic studies has served to characterize two weak binding ligands. These initial results prompted further elucidation of the binding properties of EcIspF by analyzing cytosine derivatives again using crystallography and SPR. The cytosine-binding site of EcIspF can tolerate small structural modifications of the pyrimidine, as evidenced by binding of FLUC. Modifications to the ribose, particularly at C2', are detrimental to binding affinity but do not preclude ligand binding as seen in the complexes with AraCMP and CDV. The incorporation of solvent mediated hydrogen-bonding interactions, linking functional groups on the ligands to the enzyme, appears to compensate for alterations in the structure of the ligands compared to substrate.
###end p 58
###begin p 59
###xml 212 213 212 213 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">K</italic>
###xml 213 214 213 214 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sub>
###xml 294 296 293 295 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref39">39</xref>
###xml 297 299 296 298 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref40">40</xref>
###xml 294 299 293 298 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="bibr" rid="ref39">39</xref>,<xref ref-type="bibr" rid="ref40">40</xref></sup>
###xml 483 485 482 484 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">13</bold>
###xml 524 526 523 525 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 659 661 658 660 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref35">35</xref>
###xml 807 809 806 808 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
Generally, when a nucleoside or nucleotide represents a fragment of substrate, this fragment alone does not contribute significantly to binding affinity. This is clearly the case for the enzyme LpxC, which has a Km >20 mM for UDP-GlcNAc and 2.1 muM for UDP-3-acyl-GlcNAc, the natural substrate.39,40 In such cases, potent inhibition might best be sought by targeting part of the active site that does not belong to the nucleotide binding pocket. The tight binding of the hydroxamate 13, postulated to bind the active site Zn2+, provides support for incorporation of metal binding moieties to design potent inhibitors. While hydroxamates can lack specificity,(35) incorporation of such a group onto cytosine analogues offers potential as a strategy to improve selectivity and potency for novel inhibitors of EcIspF.
###end p 59
###begin title 60
Experimental Section
###end title 60
###begin title 61
Hierarchical Filtering
###end title 61
###begin p 62
###xml 84 86 84 86 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref29">29</xref>
###xml 607 609 607 609 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref41">41</xref>
###xml 662 664 662 664 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref42">42</xref>
###xml 718 720 718 720 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref43">43</xref>
We used the same virtual screening database that was compiled for a previous study.(29) In short, this database contained the three-dimensional structures of small molecules stored in the Available Chemicals Directory and of screening compounds supplied by five companies, namely Ambinter, Asinex, ChemStar, InterBioScreen, and Tripos. In total, 826952 commercially available compounds were stored in this database. Filtering for compounds that possessed at least two hydrogen bond donors, two hydrogen bond acceptors, and one hydrophobic region (a five- or six-membered ring) was performed using SELECTOR.(41) The pharmacophore search was performed using UNITY(42) with the Lipinski's "rule of five" check activated.(43)
###end p 62
###begin title 63
Docking
###end title 63
###begin p 64
###xml 45 47 45 47 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 77 79 77 79 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref26">26</xref>
###xml 95 97 95 97 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref44">44</xref>
Ligands were docked into the binding site of EcIspF (PDB ) using FlexX v1.3.(26) The DrugScore(44) scoring function was applied during the placement and construction phase and for ranking.
###end p 64
###begin title 65
Protein Preparation
###end title 65
###begin p 66
###xml 84 91 84 91 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 152 154 152 154 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref16">16</xref>
###xml 272 274 272 274 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 277 279 277 279 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 84 91 <span type="species:ncbi:562">E. coli</span>
All chemicals purchased were of the highest purity available. IspF was expressed in E. coli strain BL21 (DE3) and purified following published methods.(16) The protein concentration was determined spectrophotometrically using a theoretical extinction coefficient of 8370 M-1.cm-1 at 280 nm and purity assessed as being greater than 95% by SDS-PAGE and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
###end p 66
###begin title 67
SPR Biosensor Studies
###end title 67
###begin p 68
###xml 197 199 197 199 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 339 341 338 340 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 358 359 357 358 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 391 393 390 392 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 471 473 470 472 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 475 477 474 476 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 579 581 577 579 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 727 729 724 726 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 838 840 835 837 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 948 950 938 940 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;1</sup>
###xml 1155 1157 1145 1147 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 1341 1343 1331 1333 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
SPR experiments were performed on a Biacore 3000 (Biacore, Uppsala, Sweden) instrument with CM5 research grade chips (Biacore, Uppsala, Sweden). Sensorgrams were recorded at a frequency of 2.5 Hz. EcIspF was immobilized using amine-coupling chemistry. Briefly, the sensor chip surface was activated with three 6 min injections at 5 muL min-1 of a mixture of N-hydroxysuccinimide at 115 mg mL-1 and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride at 750 mg mL-1. EcIspF was diluted with 10 mM acetate buffer pH 5.5 to a final concentration of approximately 100 mug mL-1 and applied to the chip so that readings between 4500 and 5500 response units were obtained. After immobilization, a 6 min injection at 5 muL min-1 of 1 M ethanolamine was used to quench excess active succinamide ester groups. SPR binding experiments with EcIspF were performed at 10 degreesC in 50 mM sodium phosphate pH 7 and 2 mM MgCl at a flow rate of 30 muL min-1. The sensor surface was regenerated between experiments by applying the running buffer for 20 min to dissociate any ligand complex. This was followed by a further 20 min stabilization period. Immobilized EcIspF is not amenable to more stringent and rapid regeneration conditions (data not shown). The 40 min total regeneration time between experiments helped to eliminate any carry-over of EcIspF bound to ligand. A concentration series, ranging from 0.1 muM to 10 mM, of ligand was typically run in these experiments. Each injection at a given concentration was repeated three times. Blank injections were included for each measurement series and subtracted from the data. The equilibrium (steady state) binding curves were analyzed by nonlinear regression and fit to a one-to-one Langmuir binding model. All ligands assessed by SPR were greater than 95% purity as established by high-performance liquid chromatography or combustion analysis.
###end p 68
###begin title 69
Crystallization and Structure Determination
###end title 69
###begin p 70
###xml 218 219 210 211 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl6" ref-type="table">6</xref>
###xml 365 366 357 358 <sup xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 470 471 462 463 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="tbl6" ref-type="table">6</xref>
###xml 607 609 593 595 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 630 632 616 618 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6b</bold>
###xml 634 635 620 621 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 785 787 771 773 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 997 999 974 976 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref45">45</xref>
###xml 1042 1044 1019 1021 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref46">46</xref>
###xml 1063 1065 1040 1042 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 1075 1076 1052 1053 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 1143 1145 1120 1122 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref47">47</xref>
###xml 1182 1184 1159 1161 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 1229 1231 1206 1208 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
###xml 1241 1242 1218 1219 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">6</bold>
###xml 1273 1274 1250 1251 <bold xmlns:mml="http://www.w3.org/1998/Math/MathML">7</bold>
###xml 1355 1357 1332 1334 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref48">48</xref>
###xml 1388 1390 1365 1367 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref49">49</xref>
###xml 1450 1452 1427 1429 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref50">50</xref>
###xml 1460 1462 1437 1439 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref51">51</xref>
###xml 1508 1510 1485 1487 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref52">52</xref>
###xml 1546 1548 1523 1525 <xref xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ref53">53</xref>
###xml 808 811 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
###xml 1247 1250 <span type="species:ncbi:11232?0.9015317286652079">CDV</span>
Crystals were obtained by vapor diffusion at 20 degreesC with 3 muL hanging drops over a 250 muL reservoir solution. Ligand cocrystallization conditions varied depending on the ligand and protein concentrations (Table 6). After 1-10 days, crystals displaying one of two morphologies, cubic blocks or plates, grew to an average size of 0.4 mm and 0.4 x 0.4 x 0.05 mm3, respectively. Crystals were harvested from the drops and soaked in a mixture of cryoprotectant (Table 6) and mother liquor for approximately 30 s and then cooled in a nitrogen gas stream at -170 degreesC for data collection. Data sets for EcIspF in complex with 6b, 7, and AraCMP were measured on beamline ID29 with a Q210 2D detector (Area Detector Systems Corp.) at the European Synchrotron Radiation Facility, and EcIspF in complex with CDV and FLUC were measured in-house using an RU-200 rotating-anode generator (Cu Kalpha, lambda = 1.5418 A) with an R-Axis IV image plate detector (Rigaku). Data were processed with MOSFLM(45) and scaled using the CCP4 program suite.(46) The complexes of EcIspF with 7, AraCMP, and FLUC were solved by molecular replacement with AMoRe(47) using a monomer from the published EcIspF structure (PDB ). Complex structures of EcIspf with 6 and CDV were derived from the 7 complex structure by rigid body refinement. The models were refined with REFMAC(48) using established protocols,(49) together with several rounds of manual alteration in COOT(50) or O.(51) Superpositions were calculated using LSQMAN(52) and figures produced using PyMOL.(53)
###end p 70
###begin title 71
###xml 34 36 34 36 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Ec</italic>
Co-Crystallization Conditions for EcIspF Complexes
###end title 71
###begin title 72
Acknowledgement
###end title 72
###begin p 73
Funded by the Scottish Funding Council, the Biotechnology and Biological Sciences Research Council BBS/B/14434, The Wellcome Trust 082596 and 083481, and Inpharmatica Ltd. We thank the European Synchrotron Radiation Facility, Grenoble, for synchrotron time, our colleagues for useful discussions, and Dr. John Butler for assistance with SPR.
###end p 73
###begin title 74
References
###end title 74
###begin article-title 75
Biochemistry of polyisoprenoid biosynthesis.
###end article-title 75
###begin article-title 76
###xml 195 215 195 215 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Scenedesmus obliquus</italic>
###xml 195 215 <span type="species:ncbi:3088">Scenedesmus obliquus</span>
Biosynthesis of isoprenoids (carotenoids, sterols, prenyl side chains of chlorophylls, and plastoquinone) via a novel pyruvate/glyceraldehyde 3-phosphate non-mevalonate pathway in the green alga Scenedesmus obliquus.
###end article-title 76
###begin article-title 77
The non-mevalonate pathway of isoprenoids: genes, enzymes, and intermediates.
###end article-title 77
###begin article-title 78
The non-mevalonate pathway of isoprenoid precursor biosynthesis.
###end article-title 78
###begin article-title 79
Isoprenoid biosynthesis in bacteria: a novel pathway for the early steps leading to isopentenyl diphosphate.
###end article-title 79
###begin article-title 80
The discovery of a mevalonate-independent pathway for isoprenoid biosynthesis in bacteria, algae and higher plants.
###end article-title 80
###begin article-title 81
###xml 2 3 2 3 <sub xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 142 167 142 167 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Phaeodactylum tricornutum</italic>
###xml 172 188 172 188 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Nitzschia ovalis</italic>
###xml 127 141 <span type="species:ncbi:2858">marine diatoms</span>
###xml 142 167 <span type="species:ncbi:2850">Phaeodactylum tricornutum</span>
CO2 as main carbon source for isoprenoid biosynthesis via the mevalonate-independent methylerythritol 4-phosphate route in the marine diatoms Phaeodactylum tricornutum and Nitzschia ovalis.
###end article-title 81
###begin article-title 82
###xml 77 99 77 99 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Prototheca wickerhamii</italic>
###xml 77 99 <span type="species:ncbi:3111">Prototheca wickerhamii</span>
Multiple metabolic roles for the nonphotosynthetic plastid of the green alga Prototheca wickerhamii.
###end article-title 82
###begin article-title 83
The role of lateral gene transfer in the evolution of isoprenoid biosynthesis pathways.
###end article-title 83
###begin article-title 84
###xml 34 50 34 50 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 34 50 <span type="species:ncbi:562">Escherichia coli</span>
Identification of novel essential Escherichia coli genes conserved among pathogenic bacteria.
###end article-title 84
###begin article-title 85
Planting the seeds of new antimalarial drugs.
###end article-title 85
###begin article-title 86
###xml 0 16 0 16 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 162 163 162 163 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 171 172 171 172 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 0 16 <span type="species:ncbi:562">Escherichia coli</span>
Escherichia coli engineered to synthesize isopentenyl diphosphate and dimethylallyl diphosphate from mevalonate: a novel system for the genetic analysis of the 2-C-methyl-d-erythritol 4-phosphate pathway for isoprenoid biosynthesis.
###end article-title 86
###begin article-title 87
Fosmidomycin for malaria.
###end article-title 87
###begin article-title 88
Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs.
###end article-title 88
###begin article-title 89
###xml 70 71 70 71 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 79 80 79 80 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 108 109 108 109 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 117 118 117 118 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
Biosynthesis of terpenoids: YgbB protein converts 4-diphosphocytidyl-2C-methyl-d-erythritol 2-phosphate to 2C-methyl-d-erythritol 2,4-cyclodiphosphate.
###end article-title 89
###begin article-title 90
###xml 14 15 14 15 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 23 24 23 24 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
Structure of 2C-methyl-d-erythritol 2,4- cyclodiphosphate synthase: an essential enzyme for isoprenoid biosynthesis and target for antimicrobial drug development.
###end article-title 90
###begin article-title 91
###xml 28 29 28 29 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 37 38 37 38 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
Structure and mechanism of 2C-methyl-d-erythritol 2,4-cyclodiphosphate synthase. An enzyme in the mevalonate-independent isoprenoid biosynthetic pathway.
###end article-title 91
###begin article-title 92
###xml 14 15 14 15 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 23 24 23 24 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
Structure of 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase involved in mevalonate-independent biosynthesis of isoprenoids.
###end article-title 92
###begin article-title 93
###xml 14 15 14 15 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 23 24 23 24 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 69 91 69 91 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Haemophilus influenzae</italic>
###xml 69 91 <span type="species:ncbi:727">Haemophilus influenzae</span>
Structure of 2C-methyl-d-erythrol-2,4-cyclodiphosphate synthase from Haemophilus influenzae: activation by conformational transition.
###end article-title 93
###begin article-title 94
###xml 38 39 38 39 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 47 48 47 48 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
Structure and catalytic mechanism of 2C-methyl-d-erythritol 2,4-cyclodiphosphate (MECDP) synthase, an enzyme in the non-mevalonate pathway of isoprenoid synthesis.
###end article-title 94
###begin article-title 95
###xml 17 29 17 29 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Mycobacteria</italic>
###xml 31 32 31 32 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 40 41 40 41 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
The structure of Mycobacteria 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase, an essential enzyme, provides a platform for drug discovery.
###end article-title 95
###begin article-title 96
###xml 21 37 21 37 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 39 40 39 40 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 48 49 48 49 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 21 37 <span type="species:ncbi:562">Escherichia coli</span>
A double mutation of Escherichia coli 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase disrupts six hydrogen bonds with, yet fails to prevent binding of, an isoprenoid diphosphate.
###end article-title 96
###begin article-title 97
###xml 74 90 74 90 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 92 93 92 93 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 101 102 101 102 <sc xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sc>
###xml 74 90 <span type="species:ncbi:562">Escherichia coli</span>
The identification of isoprenoids that bind in the intersubunit cavity of Escherichia coli 2C-methyl-d-erythritol-2,4-cyclodiphosphate synthase by complementary biophysical methods.
###end article-title 97
###begin article-title 98
Hexameric assembly of the bifunctional methylerythritol 2,4-cyclodiphosphate synthase and protein-protein associations in the deoxy-xylulose-dependent pathway of isoprenoid precursor biosynthesis.
###end article-title 98
###begin article-title 99
###xml 62 82 62 82 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Campylobacter jejuni</italic>
###xml 62 82 <span type="species:ncbi:197">Campylobacter jejuni</span>
Biosynthesis of isoprenoids: a bifunctional IspDF enzyme from Campylobacter jejuni.
###end article-title 99
###begin article-title 100
A fast flexible docking method using an incremental construction algorithm.
###end article-title 100
###begin article-title 101
Comparing protein-ligand docking programs is difficult.
###end article-title 101
###begin article-title 102
###xml 69 74 <span type="species:ncbi:9606">Human</span>
Subnanomolar Inhibitors from Computer Screening: A Model Study Using Human Carbonic Anhydrase II.
###end article-title 102
###begin article-title 103
Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis.
###end article-title 103
###begin article-title 104
Molecular complexity and its impact on the probability of finding leads for drug discovery.
###end article-title 104
###begin article-title 105
Is there a difference between leads and drugs? A historical perspective.
###end article-title 105
###begin article-title 106
Fluorescent inhibitors for IspF, an enzyme in the non-mevalonate pathway for isoprenoid biosynthesis and a potential target for antimalarial therapy.
###end article-title 106
###begin article-title 107
Fludarabine, cytarabine, and mitoxantrone (FLAM) for the treatment of relapsed and refractory adult acute lymphoblastic leukemia. A phase study by the Polish Adult Leukemia Group (PALG).
###end article-title 107
###begin article-title 108
Antiviral acyclic nucleoside phosphonates structure activity studies.
###end article-title 108
###begin article-title 109
Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies.
###end article-title 109
###begin article-title 110
Carbohydroxamido-oxazolidines: antibacterial agents that target lipid A biosynthesis.
###end article-title 110
###begin article-title 111
The design of leadlike combinatorial Libraries.
###end article-title 111
###begin article-title 112
Ligand efficiency: a useful metric for lead selection.
###end article-title 112
###begin article-title 113
Fragment-based drug design: how big is too big?.
###end article-title 113
###begin article-title 114
###xml 6 7 6 7 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">O</italic>
###xml 9 10 9 10 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 31 32 31 32 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 66 82 66 82 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 66 82 <span type="species:ncbi:562">Escherichia coli</span>
UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase of Escherichia coli is a zinc metalloenzyme.
###end article-title 114
###begin article-title 115
Drug-like properties and the causes of poor solubility and poor permeability.
###end article-title 115
###begin article-title 116
Knowledge-based scoring function to predict protein-ligand interactions.
###end article-title 116
###begin article-title 117
Automation of the collection and processing of X-ray diffraction data-a generic approach.
###end article-title 117
###begin article-title 118
Collaborative Computational Project, Number 4. The CCP4 Suite: Programs for Protein Crystallography.
###end article-title 118
###begin article-title 119
Implementation of molecular replacement in AMoRe.
###end article-title 119
###begin article-title 120
Refinement of macromolecular structures by the maximum-likelihood method.
###end article-title 120
###begin article-title 121
###xml 38 39 38 39 <italic xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
Structure and reactivity of LpxD, the N-acyltransferase of lipid A biosynthesis.
###end article-title 121
###begin article-title 122
Coot: model-building tools for molecular graphics.
###end article-title 122
###begin article-title 123
Improved methods for building protein models in electron density maps and the location of errors in these models.
###end article-title 123
###begin article-title 124
Use of non-crystallographic symmetry in protein structure refinement.
###end article-title 124

